| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8349804 | Pharmacological Reports | 2017 | 20 Pages |
Abstract
Due to its inhibition of LTC4 synthesis, troglitazone therapy is an interesting potential therapeutic approach in asthma and other LTC4 related inflammatory disorders.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Emilia Luczak, Joanna Wieczfinska, Milena Sokolowska, Ewa Pniewska, Daria Luczynska, RafaÅ Pawliczak,